Roche’s Phase III ALLEGORY study for Gazyva® (obinutuzumab) in systemic lupus erythematosus (SLE) met its primary and all key secondary endpoints. These “unprecedented” results demonstrate Gazyva’s potential to effectively control disease activity and may delay or prevent further organ damage in people with SLE.
Eli Lilly has announced a $3 billion investment to build a new, state-of-the-art manufacturing facility in Katwijk, Netherlands. Located in the Leiden Bio Science Park, the advanced plant will significantly expand the company’s capacity for its growing portfolio of oral medicines, including the oral GLP-1 drug orforglipron.
Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the FDA for STELARA® (ustekinumab) to treat children aged two years and older with moderately to severely active ulcerative colitis. The filing is supported by data from the Phase 3 UNIFI Jr clinical trial, aiming to address the significant unmet needs for this pediatric patient population.
AbbVie announced third-quarter 2025 net revenues of $15.776 billion, a 9.1% increase, fueled by strong growth from its immunology drugs Skyrizi and Rinvoq. GAAP diluted EPS was $0.10, impacted by IPR&D expenses, while adjusted diluted EPS was $1.86. Following the strong quarter, AbbVie raised its full-year 2025 adjusted diluted EPS guidance to $10.61 – $10.65.
Gilead Sciences (GILD) reported strong Q3 2025 financial results, with total revenues of $7.8 billion and non-GAAP diluted EPS jumping 22% to $2.47. The performance was driven by a 4% rise in its core business (excluding Veklury), led by its HIV franchise and $3.7 billion in Biktarvy sales. Despite a decline in Veklury and Cell Therapy revenue, the company raised its full-year 2025 diluted EPS guidance.
Eli Lilly reported blockbuster Q3 2025 earnings, with revenue hitting $17.6 billion on 54% year-over-year growth. The financial success was overwhelmingly driven by its incretin portfolio, particularly the high-demand GLP-1 drugs Mounjaro and Zepbound, which saw their sales soar. Following the strong performance and R&D momentum including positive Phase 3 data for the oral obesity drug orforglipron Lilly significantly raised its full-year 2025 revenue and EPS guidance.
Eli Lilly is building the pharmaceutical industry’s most powerful supercomputer in collaboration with NVIDIA to create an “AI factory.” This massive system, featuring over 1,000 NVIDIA DGX B300 GPUs, will leverage decades of data to train specialized AI models, dramatically accelerating drug discovery and development while running on 100% renewable electricity.
For the third quarter that concluded on September 30, 2025, IQVIA Holdings Inc. (NYSE: IQV) posted solid financial results. The company’s profit and revenue were [Read More…]
Eli Lilly has received FDA approval for a new single-injection maintenance dose of Omvoh (mirikizumab-mrkz) for adults with moderately to severely active ulcerative colitis. This approval simplifies the treatment regimen from two monthly injections down to just one, offering the same proven efficacy in a more convenient format. The new 200 mg/2 mL prefilled pens and syringes are expected to be available in the U.S. in early 2026.
New 96-week data from the Phase 3 GALAXI and GRAVITI studies show high rates of sustained remission for TREMFYA® (guselkumab) in Crohn’s disease. At two years, over 86% of patients on maintenance doses achieved clinical remission, reinforcing its long-term efficacy as the only fully subcutaneous IL-23 inhibitor for the condition.
